It was reported on Thursday that Shanghai ChemPartner, a drug discovery and development company, has named Steven Yu, PhD as its new vice president of Regulated Bioanalysis at the company headquarters in Shanghai, China.

Dr Yu has over 15 years of experience in drug development with a focus on assay development and validation, biomarker development, immunogenicity assessment, biotransformation assessment, and clinical dose selection and trial design.

Dr Yu has spent most of his career in the US with global pharmaceutical companies including Amgen, Boehringer Ingelheim, Shire, and Takeda.